GHRS News and Press, GH Research PLC

Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior antidepressant treatment failures DUBLIN, March 25, 2026 (GLOBE NE...

2026-03-10 17:28:09 ET Thesis GH Research PLC ( GHRS ) reported an FY25 GAAP EPS of -$0.79. This was somewhat expected, as they’re still continuing investment in clinical development. The firm also managed to end the year with a decent cash position of about $280....

2026-03-10 10:03:22 ET Eddie Hickman from Guggenheim issued a price target of $34.00 for GHRS on 2026-03-10 10:40:00. The adjusted price target was set to $34.00. At the time of the announcement, GHRS was trading at $15.81. The overall price target consensus is at $35.67...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions Canada NewsWire Issued on behalf of Cybin D/B/A Helus Pharma USANewsGroup.com News Commentary VANCOUVER, BC , March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approachi...

2026-03-05 17:00:21 ET More on GH Research GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision GH Research surges as FDA lifts clinical hold on depression therapy GH Research surges on upcoming late-stage trial update Seeking Alpha’s Quant R...

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025 DUBL...

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Canada NewsWire Issued on behalf of Helus Pharma VANCOUVER, BC , Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approva...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-01-23 15:04:50 ET from RBC Capital issued a price target of $40.00 for GHRS on 2026-01-23 19:24:14. The adjusted price target was set to $40.00. At the time of the announcement, GHRS was trading at $16.73. The overall price target consensus is at $34.20 with high pr...